The Purdue University Center for Cancer Research (PCCR) was established as an NCI basic science cancer center in 1978. As such, the PCCR's mission focuses on basic discovery - discovery that is the foundation through which the PCCR fosters innovative cancer solutions. Notably, the PCCR not only supports basic discovery but also facilitates discovery application and, where possible, positions discoveries for transfer to the public domain. Purdue strengths in engineering, veterinary medicine, nutrition science, chemistry, medicinal chemistry, pharmacy, structural biology, and biological sciences, form the core foundation upon which the PCCR facilitates discovery centered on understanding the biology of the cancer cell, developing innovative technology to probe cancer-related phenomena, creating diagnostic and imaging tools, and synthesizing unique therapeutic chemical entities that can be delivered to the cancer cell by novel technology. To facilitate the mission of discovery, the PCCR has established a transdisciplinary environment that focuses PCCR core strengths on providing novel solutions to cancer problems. As a matrix center, PCCR leadership draws on core capabilities through its 97 members from 18 academic departments and 6 colleges across Purdue, to organize an infrastructure based on four Research Programs: Chemical and Structural Biology (CSB), Cell Identity and Signaling (CIS), Medicinal Chemistry (MC), and Drug Delivery and Molecular Sensing (DDMS). The PCCR expedites discovery through management of 7 Shared Resources (Flow Cytometry and Cell Separation (FC-SR), DNA Sequencing (SEQ-SR), Macromolecular Crystallography (MM-SR), Mass Spectrometry (MS-SR), Nuclear Magnetic Resonance (NMR-SR), Biological Evaluation (BE-SR) and Transgenic Mouse (TMCF-SR)) which provide researchers access to state-of-the-art expertise to analyze cells, nucleic acids and proteins, to determine detailed molecular structures that can be used to design drugs, to evaluate targets/drugs in vivo, and to develop new animal models of cancer. The PCCR fosters a remarkable breadth of cancer research spanning clinical evaluations of dogs with spontaneous malignancies as an evaluative process in drug development and validation of targets and technologies, to probing the fundamentals of molecular motion through interferometry and determining its application for innovative cancer solutions, and the application of the pioneering technology that is based on ionizing molecules in ambient conditions for mass spectrometry analysis to identify cancer markers and which opened doors for additional technological assessments and mechanistic biological studies. Finally, the PCCR maintains the Essential Characteristics for a Cancer Center including exceptional Physical Space, effective Organizational Capabilities that provide the foundation for innovative cancer research, a Transdisciplinary Collaborative environment that facilitates fundamental discovery with a Cancer Focus, exceptional Institutional Commitment to expand and enhance cancer research at Purdue, and outstanding Center Director leadership that drives the development of cancer solutions.

Public Health Relevance

Overall Component: Project Narrative As a basic science cancer center, the PCCR, through its fundamental research effort, serves its state, country and the world through innovative discovery and its application to cancer solutions. Through drug discovery, drug delivery, imaging technology and biomarker discovery, the PCCR applies innovative solutions to major cancer problems.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023168-35
Application #
8855792
Study Section
Special Emphasis Panel (ZCA1-RTRB-R (J1))
Program Officer
Ptak, Krzysztof
Project Start
1997-04-01
Project End
2020-06-30
Budget Start
2015-07-09
Budget End
2016-06-30
Support Year
35
Fiscal Year
2015
Total Cost
$1,527,821
Indirect Cost
$542,130
Name
Purdue University
Department
Type
Organized Research Units
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Norvil, Allison B; Petell, Christopher J; Alabdi, Lama et al. (2018) Dnmt3b Methylates DNA by a Noncooperative Mechanism, and Its Activity Is Unaffected by Manipulations at the Predicted Dimer Interface. Biochemistry 57:4312-4324
Chambers, Andrea M; Wang, Jiao; Lupo, Kyle B et al. (2018) Adenosinergic Signaling Alters Natural Killer Cell Functional Responses. Front Immunol 9:2533
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Wu, Heng; Post, Carol Beth (2018) Protein Conformational Transitions from All-Atom Adaptively Biased Path Optimization. J Chem Theory Comput 14:5372-5382
Denton, Kyle E; Wang, Sijie; Gignac, Michael C et al. (2018) Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8. SLAS Discov 23:417-428
Liu, Wenting; Zhong, Yi-Fang; Liu, Liu-Yi et al. (2018) Solution structures of multiple G-quadruplex complexes induced by a platinum(II)-based tripod reveal dynamic binding. Nat Commun 9:3496
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Kong, Yifan; Cheng, Lijun; Mao, Fengyi et al. (2018) Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J Biol Chem 293:14328-14341
Ali, Remah; Brown, Wells; Purdy, Stephen Connor et al. (2018) Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. Cell Death Dis 9:976
Jakubison, Brad L; Schweickert, Patrick G; Moser, Sarah E et al. (2018) Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment. Mol Oncol 12:1104-1124

Showing the most recent 10 out of 436 publications